Quanterix
Maker of Simoa, an ultra-sensitive blood test platform for Alzheimer's and other biomarkers.
On the record
Checkpoint: FDA 510(k) decision on LucentAD Complete multi-analyte Alzheimer's blood test
The call
Quanterix has real lab infrastructure and payer inroads but is racing an FDA decision against already-cleared rivals while burning cash.
Quanterix builds machines and lab services that detect tiny amounts of proteins in blood, especially for early Alzheimer's detection. The company owns installed equipment, FDA approvals, and some insurance coverage, but larger rivals like Thermo Fisher (which owns Olink), Roche, and Fujirebio already compete in the same space and have more money and reach; Fujirebio has already won FDA clearance for an Alzheimer's blood test and is suing Quanterix. What could change the picture: winning an FDA decision on Quanterix's own Alzheimer's test in the second half of 2026 and getting insurance companies to actually pay for it instead of competitors' versions, though the company is burning cash today and has new leadership trying to turn it around.
Why
01
AI pressure: None apparent. No AI agent or model competes directly with Simoa hardware; AI mainly assists in interpreting results, not replacing the assay. Could AI do the core job? Unlikely.
02
Bigger players: Fujirebio Diagnostics and Roche Diagnostics. Fujirebio already sells an FDA-cleared Alzheimer's blood test and is suing Quanterix over patents, while Quanterix still waits on its own clearance. Could a giant copy it? Yes, easily.
03
What protects it. About 2,300 installed Simoa instruments, a CLIA lab, Breakthrough Designation, and new Akoya tissue tech give it a wider diagnostics footprint than a single test.
What would change this call
FDA 510(k) decision on Quanterix's LucentAD Complete test in H2 2026. Clearance would let Quanterix compete directly with Fujirebio's already-cleared Alzheimer's test.
A second payer beyond Anthem announcing coverage within 6 months of July 1, 2026. Would show payer adoption spreading rather than staying limited to one insurer.
Outcome of Fujirebio's ongoing IP litigation against Quanterix. A loss could block or tax Quanterix's ability to sell its Alzheimer's blood test.
A second payer beyond Anthem announcing coverage within 6 months of July 1, 2026. Would show payer adoption spreading rather than staying limited to one insurer.
Outcome of Fujirebio's ongoing IP litigation against Quanterix. A loss could block or tax Quanterix's ability to sell its Alzheimer's blood test.
Key numbers
- $103M cash and securities
- Q1 2026 revenue $36.4M, up 20% reported, organic decline
- Q1 2026 adjusted EBITDA loss $9.8M
Named risks
- FDA may delay or reject 510(k) clearance for LucentAD Complete expected H2 2026.
- Core organic revenue continues declining despite acquisition-driven headline growth.
- Ongoing Fujirebio patent litigation could restrict commercialization or impose damages.
- Shareholder class-action investigations tied to 2024 accounting restatement remain unresolved.
- Cash position of $103 million (2026-05-07) limits runway if breakeven target slips.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Fujirebio Diagnostics | losing to | FDA-cleared Alzheimer's blood test since 2025-05-16, ahead of Quanterix's pending 510(k); litigation active as of 2025-11-18 |
| Meso Scale Discovery (MSD) | losing to | Peer-reviewed Dec 2024 comparison ranked MSD's S-plex most sensitive, ahead of Quanterix's SP-X |
| Olink (Thermo Fisher) | contesting | Dec 2024 study ranked Olink Target 48 more sensitive than Quanterix's SP-X |
| Roche Diagnostics | gaining on | Roche received CE mark for a blood-based Alzheimer's pathology test on 2026-05-12 |
| Thermo Fisher Scientific | contesting | Owns Olink, competes on scale and bundling in ultra-sensitive protein diagnostics as of 2026 |
Questions people ask
- Is Quanterix profitable in 2026?
- No. Quanterix posted a $9.8 million adjusted EBITDA loss in Q1 2026 (reported 2026-05-07) and net margin remains deeply negative. Management targets cash-flow breakeven in H2 2026, but this is a stated goal, not an achieved result, and organic revenue is still declining.
- Who is Quanterix's biggest competitor?
- Fujirebio Diagnostics is the most pressing rival: it received FDA clearance for its Lumipulse Alzheimer's blood test on 2025-05-16, beating Quanterix to market, and the two companies are in active federal litigation as of 2025-11-18. Thermo Fisher (via Olink) and Roche also compete directly.
- Could AI replace Quanterix's core business?
- Unlikely to replace it directly. Quanterix's wet-lab Simoa immunoassay detection and FDA regulatory clearances are not AI-replicable. AI shows up only as a distribution layer, such as the May 2026 Tempus AI partnership to route LucentAD Complete orders through Tempus's care-gap platform.
- Did Quanterix's acquisition of Akoya Biosciences work?
- The Akoya deal closed 2025-07-08, adding spatial biology and ~1,396 installed instruments, bringing combined cash to about $163 million with no debt at close. But by Q1 2026, cash had fallen to $103 million and core organic revenue was declining despite $85 million in annualized synergies.
- Will Quanterix get FDA approval for its Alzheimer's blood test?
- Quanterix submitted a 510(k) for its multi-analyte Alzheimer's blood test on 2026-02-04, building on prior FDA Breakthrough Device Designation, with a decision expected in H2 2026. Rival Fujirebio already secured FDA clearance for a similar test back on 2025-05-16.
- Who owns Quanterix?
- Quanterix is a publicly traded company on Nasdaq under ticker QTRX, with no controlling parent; it IPO'd on 2017-12-07. It is itself an acquirer, having closed its purchase of Akoya Biosciences on 2025-07-08, with legacy Quanterix shareholders retaining about 71% of the combined company.
Timeline
- 2026-07-14Anthem Blue Cross Blue Shield establishes commercial coverage for LucentAD Complete, effective 2026-07-01
- 2026-05-07Q1 2026 results: $36.4M revenue, $9.8M adjusted EBITDA loss, $103M cash, organic decline
- 2026-05-06Quanterix and Tempus AI announce collaboration to integrate LucentAD Complete into Tempus Next platform
- 2026-02-04Quanterix submits FDA 510(k) for multi-analyte algorithmic Alzheimer's blood test
- 2026-01-19Everett Cunningham becomes President and CEO, succeeding Masoud Toloue
- 2025-11-18Fujirebio v. Quanterix litigation: counterclaim motions to dismiss briefed
- 2025-07-08Quanterix completes acquisition of Akoya Biosciences, combined cash ~$163M, no debt
- 2025-05-16Fujirebio's Lumipulse test becomes first FDA-cleared blood-based Alzheimer's diagnostic
- 2025-01-10Quanterix announces agreement to acquire Akoya Biosciences
- 2024-11Quanterix discloses multi-year accounting error, dismisses Ernst & Young, appoints KPMG
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Quanterix Corp. Company & People (2025-06-12)
- Quanterix (QTRX) Company Profile & Description (2026-07-17)
- Quanterix Completes Acquisition of Akoya Biosciences (2025-07-08)
- Quanterix Releases Financial Results for the First Quarter of 2026 (2026-05-07)
- gurufocus.com (2026-07-24)
- Quanterix (QTRX) Earnings Call Transcripts
- Quanterix (QTRX) Q1 2026 Earnings Transcript (2026-05-07)
- Quanterix Q1 Earnings Call Highlights (2026-05-07)
- Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD Complete (2026-07-14)
- Quanterix to Acquire Akoya Biosciences (2025-01-10)
- Quanterix (QTRX) Number of Employees (2026-06-25)
- Rosen Law Firm Encourages Quanterix Corporation Investors to Inquire about Securities Class Action Investigati (2024-12-09)